Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06782477 | A Study of STAR-0310 in Healthy Adult Participants | PHASE1 | ACTIVE NOT_RECRUITING | 40 | — | — | Jan 7, 2025 | Jan 1, 2026 | Nov 4, 2025 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| STAR-0310 Dose 1 | EXPERIMENTAL | Participants will be randomized to receive STAR-0310 or matching placebo |
| STAR-0310 Dose 2 | EXPERIMENTAL | Participants will be randomized to receive STAR-0310 or matching placebo |
| STAR-0310 Dose 3 | EXPERIMENTAL | Participants will be randomized to receive STAR-0310 or matching placebo |
| STAR-0310 Dose 4 | EXPERIMENTAL | Participants will be randomized to receive STAR-0310 or matching placebo |
| STAR-0310 in Participants of Japanese Descent | EXPERIMENTAL | Participants will be randomized to receive STAR-0310 or matching placebo |
| Name | Type | Description |
|---|---|---|
| STAR-0310 | DRUG | STAR-0310 will be administered as a subcutaneous bolus injection. |
| Placebo | DRUG | Placebo will be administered as a subcutaneous bolus injection. |
Inclusion Criteria: * Good health as determined by the Investigator based upon a medical evaluation. * Body mass index (BMI) of 18 to 35 kg/m2 with a weight of at least 60 kg for men and at least 50 kg for women, with a maximum weight of 130 kg for any participant. * Participants of childbearing po...